X0306 4 2016-09-15 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 1 1 0 0 Chief Executive Officer Common Stock 2016-09-15 2016-09-15 4 M 0 42577 17.33 A 421161 D Common Stock 2016-09-15 2016-09-15 4 S 0 42577 94.8484 D 378584 D Common Stock 2016-09-16 2016-09-16 4 M 0 53125 38.59 A 431709 D Common Stock 2016-09-16 2016-09-16 4 S 0 53125 95.2478 D 378584 D Common Stock 2016-09-16 2016-09-16 4 M 0 41666 17.54 A 420250 D Common Stock 2016-09-16 2016-09-16 4 S 0 41666 95.967 D 378584 D Common Stock 25758 I Shares held by Bienaime Family Trust Stock Option (right to buy Common Stock) 17.33 2016-09-15 2016-09-15 4 M 0 42577 0 D 2007-12-07 2017-06-06 Common Stock 42577 117423 D Stock Option (right to buy Common Stock) 38.59 2016-09-16 2016-09-16 4 M 0 53125 0 D 2008-11-22 2018-05-21 Common Stock 53125 371875 D Stock Option (right to buy Common Stock) 17.54 2016-09-16 2016-09-16 4 M 0 41666 0 D 2007-05-20 2016-11-19 Common Stock 41666 83336 D Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime. The price in column 4 is the weighted average price. The price actually received ranged from $94.02 to $96.72. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in column 4 is the weighted average price. The price actually received ranged from $94.02 to $97.20. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Trade made pursuant to a 10b5-1 plan executed on August 17, 2015. Mr. Bienaime's former spouse will receive approximately 17% of the net proceeds from the sale of these shares pursuant to a marital separation agreement between Mr. Bienaime and his former spouse. The price in column 4 is the weighted average price. The price actually received ranged from $94.365 to $97.21. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Reflects the number of stock options outstanding after the transaction from this specific stock option grant. /s/ Laura Randall Woodhead, Attorney-in-Fact 2016-09-19